News
News Release
Cyclomedical Applications Group, LLC
Announces New Associate
Contact: James F. Lamb, Ph.D.
+1-865-670-9021
jlamb@cyclomedical.com
KNOXVILLE, Tennessee,
2010 May 27—Cyclomedical Applications Group is pleased to announce the appointment of another new Associate, expanding the range of accelerator expertise in positron emission tomography (PET) services and capabilities offered to clients.
Dr. Brian Abeysekera has more than 25 years of experience in radioisotope and radiopharmaceutical development, including production, radiochemistry, quality control, quality assurance and regulatory affairs activities in the United States and Canada. From 1985 to 2007, he worked at MDS Nordion, where he held various positions in R&D, safety and regulatory affairs. During his tenure at Nordion, Dr. Abeysekera helped establish the company as a cGMP supplier of sterile pharmaceuticals; designed, developed and validated aseptic manufacturing facilities; directed scale-up from clinical to commercial manufacturing; and developed chemistry and manufacturing sections to support FDA submissions.
He also served as Vice President, Manufacturing for Molecular Insight Pharmaceuticals where he was responsible for all aspects of supply chain management for drug products for clinical trials and commercial supply and for Contract Manufacturing contracts and services. He is now President of PharmaSPECT Inc, a company that provides cGMP and Manufacturing, Quality and Regulatory expertise to PET and SPECT radiopharmaceutical manufacturers.
Dr. James Lamb, President of Cyclomedical, announced, “We are extremely proud to announce the addition of Brian to our team. He is a well known and respected member of the nuclear medicine community, and he will play a key role in Cyclomedical assignments at cyclotron facilities around the world.”
Cyclomedical Applications Group is an organization of experienced radiopharmaceutical experts serving the radiopharmaceutical industry, especially owners and operators of medical cyclotrons dedicated to the production of positron emitting radioisotopes. It works primarily with facilities producing and distributing F-18 FDG–the most widely used positron-emitting radiopharmaceutical in PET scanning.
Consulting services offered by the company range from short-term consultation to longer-term retainer arrangements and assistance with regulatory agencies as well as cyclotron operation and FDG production problems. Contract management services range from full responsibility for a cyclotron/FDG production facility to a monitoring posture in support of an in-place management team.
Cyclomedical’s goal is to provide a full range of support expertise including FDG market research and development, facility financing, facility planning and operation, licensing and safety, and FDA regulatory issues. The company currently has operational responsibility for several cyclotron/FDG facilities and is providing cyclotron consultation services to a number of cyclotron operating companies. For more information, see the Cyclomedical web site at www.cyclomedical.com.